Safety and Efficacy of Long-term Sodium Channel Blocker Therapy for Early Rhythm Control: the EAST-AFNET 4 Trial

Overview

Journal Europace

Publisher Oxford University Press

Specialties Cardiology & Vascular Diseases
Physiology

Date 2024 May 4

PMID 38702961

Authors

Andreas Rillig

Lars Eckardt

Katrin Borof

A John Camm

Harry J G M Crijns

Andreas Goette

Gunter Breithardt

Marc D Lemoine

Andreas Metzner

Laura Rottner

Ulrich Schotten

Eik Vettorazzi

Karl Wegscheider

Antonia Zapf

Hein Heidbuchel

Stephan Willems

Larissa Fabritz

Renate B Schnabel

Christina Magnussen

Paulus Kirchhof

Affiliations

Soon will be listed here.

Abstract

Aims: Clinical concerns exist about the potential proarrhythmic effects of the sodium channel blockers (SCBs) flecainide and propafenone in patients with cardiovascular disease. Sodium channel blockers were used to deliver early rhythm control (ERC) therapy in EAST-AFNET 4.

Methods And Results: We analysed the primary safety outcome (death, stroke, or serious adverse events related to rhythm control therapy) and primary efficacy outcome (cardiovascular death, stroke, and hospitalization for worsening of heart failure (HF) or acute coronary syndrome) during SCB intake for patients with ERC (n = 1395) in EAST-AFNET 4. The protocol discouraged flecainide and propafenone in patients with reduced left ventricular ejection fraction and suggested stopping therapy upon QRS prolongation >25% on therapy. Flecainide or propafenone was given to 689 patients [age 69 (8) years; CHA2DS2-VASc 3.2 (1); 177 with HF; 41 with prior myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention; 26 with left ventricular hypertrophy >15 mm; median therapy duration 1153 [237, 1828] days]. The primary efficacy outcome occurred less often in patients treated with SCB [3/100 (99/3316) patient-years] than in patients who never received SCB [SCBnever 4.9/100 (150/3083) patient-years, P < 0.001]. There were numerically fewer primary safety outcomes in patients receiving SCB [2.9/100 (96/3359) patient-years] than in SCBnever patients [4.2/100 (135/3220) patient-years, adjusted P = 0.015]. Sinus rhythm at 2 years was similar between groups [SCB 537/610 (88); SCBnever 472/579 (82)].

Conclusion: Long-term therapy with flecainide or propafenone appeared to be safe in the EAST-AFNET 4 trial to deliver effective ERC therapy, including in selected patients with stable cardiovascular disease such as coronary artery disease and stable HF. Clinical Trial Registration ISRCTN04708680, NCT01288352, EudraCT2010-021258-20, www.easttrial.org.

Citing Articles

Detection and management of postoperative atrial fibrillation after coronary artery bypass grafting or non-cardiac surgery: a survey by the AF-SCREEN International Collaboration.

Boriani G, Imberti J, McIntyre W, Mei D, Healey J, Schnabel R Intern Emerg Med. 2025; .

PMID: 39921772 DOI: 10.1007/s11739-025-03861-2.

Selected Updates in Anti-arrhythmic Drug Therapy and Anticoagulants: 2024.

Reiffel J J Innov Card Rhythm Manag. 2025; 16(1):6144-6150.

PMID: 39897721 PMC: 11784401. DOI: 10.19102/icrm.2025.16018.

Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects.

Rienstra M, Tzeis S, Bunting K, Caso V, Crijns H, De Potter T Europace. 2024; 26(12).

PMID: 39716733 PMC: 11666470. DOI: 10.1093/europace/euae298.

[Antiarrhythmic drugs will no longer be of importance in the treatment of atrial fibrillation in the future : Pros and cons].

Metzner A, Schmidt C Herzschrittmacherther Elektrophysiol. 2024; 35(4):274-281.

PMID: 39535618 DOI: 10.1007/s00399-024-01047-5.

Antiarrhythmic drugs in the era of atrial fibrillation ablation.

Boriani G, Mei D, Imberti J Europace. 2024; 26(6).

PMID: 38700094 PMC: 11154134. DOI: 10.1093/europace/euae122.

References

Frommeyer G, Eckardt L . Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 2015; 13(1):36-47. DOI: 10.1038/nrcardio.2015.110. View

Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U . Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. Lancet. 2012; 380(9838):238-46. DOI: 10.1016/S0140-6736(12)60570-4. View

Klamer T, Bots S, Neefs J, Tulevski I, den Ruijter H, Somsen G . Rate and Rhythm Control Treatment in the Elderly and Very Elderly Patients With Atrial Fibrillation: An Observational Cohort Study of 1497 Patients. Curr Probl Cardiol. 2021; 47(10):100996. DOI: 10.1016/j.cpcardiol.2021.100996. View

Rolf S, Haverkamp W, Borggrefe M, Musshoff U, Eckardt L, Mergenthaler J . Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn Schmiedebergs Arch Pharmacol. 2000; 362(1):22-31. DOI: 10.1007/s002100000257. View

Andrade J, Wells G, Deyell M, Bennett M, Essebag V, Champagne J . Cryoablation or Drug Therapy for Initial Treatment of Atrial Fibrillation. N Engl J Med. 2020; 384(4):305-315. DOI: 10.1056/NEJMoa2029980. View

Aliot E, Capucci A, Crijns H, Goette A, Tamargo J . Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2010; 13(2):161-73. PMC: 3024037. DOI: 10.1093/europace/euq382. View

Eckardt L, Sehner S, Suling A, Borof K, Breithardt G, Crijns H . Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J. 2022; 43(40):4127-4144. PMC: 9584752. DOI: 10.1093/eurheartj/ehac471. View

Jensen M, Suling A, Metzner A, Schnabel R, Borof K, Goette A . Early rhythm-control therapy for atrial fibrillation in patients with a history of stroke: a subgroup analysis of the EAST-AFNET 4 trial. Lancet Neurol. 2022; 22(1):45-54. DOI: 10.1016/S1474-4422(22)00436-7. View

Metzner A, Suling A, Brandes A, Breithardt G, Camm A, Crijns H . Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. Europace. 2021; 24(4):552-564. PMC: 8982435. DOI: 10.1093/europace/euab200. View

10.

Rillig A, Magnussen C, Ozga A, Suling A, Brandes A, Breithardt G . Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation. 2021; 144(11):845-858. PMC: 8456351. DOI: 10.1161/CIRCULATIONAHA.121.056323. View

11.

Willems S, Borof K, Brandes A, Breithardt G, Camm A, Crijns H . Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J. 2021; 43(12):1219-1230. PMC: 8934687. DOI: 10.1093/eurheartj/ehab593. View

12.

Remme C, Heijman J, Gomez A, Zaza A, Odening K . 25 years of basic and translational science in EP Europace: novel insights into arrhythmia mechanisms and therapeutic strategies. Europace. 2023; 25(8). PMC: 10450791. DOI: 10.1093/europace/euad210. View

13.

Echt D, Ruskin J . Use of Flecainide for the Treatment of Atrial Fibrillation. Am J Cardiol. 2020; 125(7):1123-1133. DOI: 10.1016/j.amjcard.2019.12.041. View

14.

Dickow J, Kany S, Cardoso V, Ellinor P, Gkoutos G, Van Houten H . Outcomes of Early Rhythm Control Therapy in Patients With Atrial Fibrillation and a High Comorbidity Burden in Large Real-World Cohorts. Circ Arrhythm Electrophysiol. 2023; 16(5):e011585. PMC: 10205477. DOI: 10.1161/CIRCEP.122.011585. View

15.

Konemann H, Dagres N, Merino J, Sticherling C, Zeppenfeld K, Tfelt-Hansen J . Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects. Europace. 2023; 25(5). PMC: 10228619. DOI: 10.1093/europace/euad091. View

16.

Kirchhof P, Camm A, Goette A, Brandes A, Eckardt L, Elvan A . Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020; 383(14):1305-1316. DOI: 10.1056/NEJMoa2019422. View

17.

Eckardt L, Haverkamp W, Gottker U, Madeja M, Johna R, Borggrefe M . Divergent effect of acute ventricular dilatation on the electrophysiologic characteristics of d,l-sotalol and flecainide in the isolated rabbit heart. J Cardiovasc Electrophysiol. 1998; 9(4):366-83. DOI: 10.1111/j.1540-8167.1998.tb00925.x. View

18.

January C, Samuel Wann L, Alpert J, Calkins H, Cigarroa J, Cleveland Jr J . 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130(23):2071-104. DOI: 10.1161/CIR.0000000000000040. View

19.

Echt D, Liebson P, Mitchell L, Peters R, BARKER A, Arensberg D . Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324(12):781-8. DOI: 10.1056/NEJM199103213241201. View

20.

Eckardt L, Wolfes J, Frommeyer G . Benefits of early rhythm control of atrial fibrillation. Trends Cardiovasc Med. 2023; 34(5):288-294. DOI: 10.1016/j.tcm.2023.04.001. View